Related references
Note: Only part of the references are listed.Evidence for Acute Neurotoxicity after Chemotherapy
Axel Petzold et al.
ANNALS OF NEUROLOGY (2010)
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis
B. Healy et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
R. Zivadinov et al.
NEUROLOGY (2008)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
D. H. Miller et al.
NEUROLOGY (2007)
Multislice brain myelin water fractions at 3T in multiple sclerosis
Joonmi Oh et al.
JOURNAL OF NEUROIMAGING (2007)
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis
J. T. Chen et al.
NEUROLOGY (2006)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a
M Hardmeier et al.
NEUROLOGY (2005)
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
RJ Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes
CM Dalton et al.
BRAIN (2004)
Interferon-β-1b slows progression of atrophy in RRMS -: Three-year follow-up in NAb- and NAb+ patients
JA Frank et al.
NEUROLOGY (2004)
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis
RA Rudick
JOURNAL OF NEUROIMAGING (2004)
Share Paper
